| 0 (0%) | 09-27 09:33 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.37 | 1-year : | 1.63 |
| Resists | First : | 1.17 | Second : | 1.39 |
| Pivot price | 0.92 |
|||
| Supports | First : | 0.81 | Second : | 0.67 |
| MAs | MA(5) : | 0.9 | MA(20) : | 0.91 |
| MA(100) : | 1.29 |
MA(250) : | 1.99 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 45 |
D(3) : | 34.8 |
| RSI | RSI(14): 46.2 |
|||
| 52-week | High : | 5.94 | Low : | 0.81 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MRKR ] has closed below upper band by 34.3%. Bollinger Bands are 61.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.96 - 0.97 | 0.97 - 0.97 |
| Low: | 0.85 - 0.86 | 0.86 - 0.87 |
| Close: | 0.94 - 0.95 | 0.95 - 0.96 |
Tue, 16 Sep 2025
Aug Setups: Does MRKR have strong EBITDA margins - Earnings Summary Report & Community Consensus Stock Picks - خودرو بانک
Thu, 28 Aug 2025
Clinical-Stage Immuno-Oncology Company Marker Therapeutics to Present Latest APOLLO Trial Updates - Stock Titan
Wed, 27 Aug 2025
Marker Therapeutics (MRKR) Falls 20.6% After Positive Clinical Study - Yahoo Finance
Tue, 26 Aug 2025
Marker Therapeutics’ Shares Leaps: What’s Behind the Rise? - timothysykes.com
Tue, 26 Aug 2025
Marker Therapeutics Reports Promising Phase 1 Study Results - TipRanks
Tue, 26 Aug 2025
Marker Therapeutics Faces Major Shift amidst Strategic Challenges - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 13 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 7 (%) |
| Held by Institutions | 26.3 (%) |
| Shares Short | 1,250 (K) |
| Shares Short P.Month | 503 (K) |
| EPS | -1.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.93 |
| Profit Margin | -271.2 % |
| Operating Margin | -494.8 % |
| Return on Assets (ttm) | -69.4 % |
| Return on Equity (ttm) | -144.7 % |
| Qtrly Rev. Growth | -26.3 % |
| Gross Profit (p.s.) | -0.81 |
| Sales Per Share | 0.41 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.71 |
| PEG Ratio | 0 |
| Price to Book value | 1.02 |
| Price to Sales | 2.28 |
| Price to Cash Flow | -1.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|